Prostate Cancer Treatment
SpectraCure AB (publ) focuses on clinical research in primary localised prostate cancer and recurrent prostate cancer, with an emphasis on organ-confined and locally recurrent disease.
- Localised prostate cancer
- Recurrent prostate cancer
The sponsor’s research activity is centered on treatment approaches for prostate tumours that remain confined to the gland or return after prior therapy.
Image-Guided and Light-Based Oncology
Its clinical programme includes interest in interstitial laser delivery, light-dose control, and MRI-linked assessment of tumour response in prostate cancer.
- Interstitial laser therapy
- Light-dose planning
- MRI response assessment
These activities reflect a therapeutic focus on precisely directed treatment for malignant tissue within the prostate.
Photodynamic and Drug-Device Therapy
The sponsor investigates the use of verteporfin in combination with its proprietary treatment system, placing it within photodynamic therapy and integrated drug-device oncology development.
- Verteporfin
- Photodynamic oncology
- Combined therapeutic systems
Research activity is directed toward cancer treatment where a photosensitising agent is paired with controlled light delivery.
Urologic Oncology and Clinical Device Development
The clinical portfolio sits within urologic oncology, with attention to treatment technologies designed for precise placement, controlled energy delivery, and tumour ablation in prostate disease.
- Urologic oncology
- Targeted tumour ablation
- Precision treatment systems
Its funded studies are concentrated in European clinical settings, supporting research into advanced approaches for prostate cancer management.
